BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cantor Fitzgerald
Baxter
Harvard Business School
Chubb
Julphar
Cipla
Accenture
US Department of Justice
Express Scripts
Boehringer Ingelheim

Generated: January 21, 2018

DrugPatentWatch Database Preview

Gadoterate meglumine - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for gadoterate meglumine and what is the scope of gadoterate meglumine patent protection?

Gadoterate meglumine
is the generic ingredient in one branded drug marketed by Guerbet and is included in one NDA. Additional information is available in the individual branded drug profile pages.

One supplier is listed for this compound.
Summary for gadoterate meglumine
Pharmacology for gadoterate meglumine

US Patents and Regulatory Information for gadoterate meglumine

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Guerbet DOTAREM gadoterate meglumine SOLUTION;INTRAVENOUS 204781-001 Mar 20, 2013 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Guerbet DOTAREM gadoterate meglumine SOLUTION;INTRAVENOUS 204781-005 Mar 31, 2017 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Guerbet DOTAREM gadoterate meglumine SOLUTION;INTRAVENOUS 204781-004 Mar 20, 2013 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Guerbet DOTAREM gadoterate meglumine SOLUTION;INTRAVENOUS 204781-002 Mar 20, 2013 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Guerbet DOTAREM gadoterate meglumine SOLUTION;INTRAVENOUS 204781-001 Mar 20, 2013 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Guerbet DOTAREM gadoterate meglumine SOLUTION;INTRAVENOUS 204781-005 Mar 31, 2017 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Guerbet DOTAREM gadoterate meglumine SOLUTION;INTRAVENOUS 204781-003 Mar 20, 2013 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Guerbet DOTAREM gadoterate meglumine SOLUTION;INTRAVENOUS 204781-002 Mar 20, 2013 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Guerbet DOTAREM gadoterate meglumine SOLUTION;INTRAVENOUS 204781-003 Mar 20, 2013 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Guerbet DOTAREM gadoterate meglumine SOLUTION;INTRAVENOUS 204781-004 Mar 20, 2013 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Baxter
Medtronic
Harvard Business School
Fuji
Merck
US Department of Justice
Chinese Patent Office
UBS
Farmers Insurance

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot